AsymBio, a subsidiary of Asymchem Group, has established integrated technology platforms including cell line development, upstream/downstream processing, conjugation toolbox, and analytics.
Fujifilm Biotechnologies expanded manufacturing and process development presence in the North East of England to support vital biomanufacturing of innovative medicines and vaccines in the United Kingdom.
WuXi Biologics partners with Sinorda on bispecific antibodies for autoimmune diseases and HanchorBio on fusion proteins for oncology and immunology.
Fourth major US manufacturing investment announced this year, advancing AstraZeneca’s historic $50 billion commitment to medicines manufacturing and R&D.
New state-of-the-art facility in Philadelphia provides integrated lab and collaboration space along with tailored guidance to help move advanced therapies from early research to clinical readiness.
AGC Biologics has partnered with Rarity PBC to provide development and GMP manufacturing of a gene therapy aimed at treating a rare, life-threatening immune disorder.
Novartis plans to establish a flagship manufacturing hub in North Carolina by 2027-2028 as part of a $23 billion investment in US infrastructure.
SK Pharmteco has announced a $6.1 million investment to expand its Rancho Cordova, California, facility with new lab and kilo-scale capabilities for solid-phase peptide synthesis and purification.
Aenova will install an additional filling and manufacturing line at the Latina, Italy, site. This expansion is an important step to meet the increasing global demand for the production of biologics.
Following the acquisition of MCE Pharma Brenntag is building a unique position in both traditional pharma and biopharma.
Merck to acquire the chromatography business of JSR Life Sciences, a leading provider of CDMO services, preclinical and translational clinical research, and bioprocessing solutions.
Fujifilm Biotechnologies has opened one of North America's largest commercial-scale cell culture biomanufacturing sites in Holly Springs, North Carolina, US.
Dinamiqs, a Siegfried company specialized in viral vector design and manufacturing, inaugurated its new cGMP manufacturing facility.
Merck's first climate-neutral production facility has opened at its Blarney site in Cork, Ireland. The €150 million new building is part of the group's €440 million investment program in Ireland.
Includes $1.2 billion in manufacturing facilities, AI, and advanced digital technologies, creating hundreds of highly skilled US jobs.
Asahi Kasei Life Science emerges as a new growth driver, uniting bioprocess solutions, CRO, and CDMO services to shape the future of healthcare under President Ken Shinomiya’s leadership.
Download this complimentary Expert Insights eBook today!
New Bay Area building marks significant progress as part of Gilead's $32 billion US investment.
Download this complimentary how-to guide today!
This Expert Insights eBook hopes to provide scientists with more information on analytical ultracentrifugation (AUC), allowing you to further your research in this field.
Bionova Scientific has opened a 10,000 square-foot state-of-the-art plasmid DNA (pDNA) development and production facility in The Woodlands, Texas.
Asahi Kasei Life Science, a division of global manufacturer Asahi Kasei, announced plans to construct a new spinning plant for its Planova virus removal filters in Nobeoka City, Miyazaki, Japan.
In a new building at the Wacker Consortium, the company's central research site, researchers are working on new manufacturing processes for biopharmaceuticals and ingredients for food and nutritional supplements.
AGC Biologics began its cell therapy process development and clinical manufacturing services on July 1, 2025, at its Yokohama Technical Center in Japan.
BASF has opened a new Good Manufacturing Practice (GMP) Solution Center in Wyandotte, Michigan, to support the supply of bioprocessing ingredients and excipients for the biopharma and pharmaceutical industries.
Ecolab Life Sciences has officially opened its new US Bioprocessing Applications Laboratory in Pennsylvania.
The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.
Primogene is an innovative biotechnology company based in Leipzig that specializes in the development of biotechnological production processes for bioactive ingredients.
Exclusive licensing and R&D collaboration between Hovione and Firstgene.
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future US home for Keytruda.
Asahi Kasei has appointed Ken Shinomiya, President of Asahi Kasei Life Science, to succeed Richard Packer as Head of Healthcare.
Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3 billion (€2.64 billion), with Regeneron Pharmaceuticals to provide US-based production of its industry-leading biologic medicines, which treat millions of patients worldwide.
To meet growing demand from the pharmaceutical industry, Asahi Kasei has established Asahi Kasei Life Science to operate its bioprocess businesses under a new organizational structure.
The Seqens Group, a global manufacturer of health, personal care, and specialty ingredients, recently announced a strategic partnership with Novonesis, a sustainable biological solutions provider.
Syngene, a global contract research, development, and manufacturing organization (CRDMO), recently announced the acquisition of its first biologics site in the USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
